تقرير
Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case.
| العنوان: | Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case. |
|---|---|
| المؤلفون: | Mutlu YG; Department of Hematology, Istanbul Medipol University, Istanbul, Türkiye., Yıgıt Kaya S; Department of Hematology, Istanbul Medipol University, Istanbul, Türkiye., Maral S; Department of Hematology, Istanbul Medipol University, Istanbul, Türkiye., Melek E; Department of Hematology, Istanbul Medipol University, Istanbul, Türkiye., Baslar Z; Department of Hematology, Istanbul University-Cerrahpasa, Istanbul, Türkiye., Kaynar L; Department of Hematology, Istanbul Medipol University, Istanbul, Türkiye., Sevindik OG; Department of Hematology, Istanbul Medipol University, Istanbul, Türkiye. |
| المصدر: | Frontiers in immunology [Front Immunol] 2023 Oct 13; Vol. 14, pp. 1276295. Date of Electronic Publication: 2023 Oct 13 (Print Publication: 2023). |
| نوع المنشور: | Case Reports |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Multiple Myeloma*/drug therapy , Antibodies, Bispecific*/therapeutic use, Male ; Humans ; Adult ; Immunotherapy, Adoptive/methods ; B-Cell Maturation Antigen |
| مستخلص: | Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific antibodies (bsAbs) and chimeric antigen receptor T cells (CAR-T), have shown remarkable success in treating MM, but their efficacy in CNS involvement remains unclear. Elranatamab, a humanized bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3-expressing T cells, has demonstrated promising results in relapsed refractory MM. However, its efficacy in treating CNS-MM has not been reported. We present a case of a 37-year-old male MM patient with CNS involvement who has been successfully treated with Elranatamab. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Mutlu, Yıgıt Kaya, Maral, Melek, Baslar, Kaynar and Sevindik.) |
| References: | Cancers (Basel). 2021 Sep 29;13(19):. (PMID: 34638393) Br J Haematol. 2013 Aug;162(4):483-8. (PMID: 23772701) J Clin Oncol. 2011 Oct 1;29(28):3805-12. (PMID: 21900099) PLoS One. 2013 Aug 05;8(8):e71754. (PMID: 23940785) Br J Haematol. 2013 Jul;162(2):281-2. (PMID: 23600765) Cancer. 2012 Mar 15;118(6):1574-84. (PMID: 21932386) Am J Surg Pathol. 2020 Jun;44(6):838-848. (PMID: 32118627) Cent Nerv Syst Agents Med Chem. 2014;14(1):23-7. (PMID: 25134940) N Engl J Med. 2019 May 2;380(18):1726-1737. (PMID: 31042825) J Immunother. 2022 Jan 1;45(1):25-34. (PMID: 34874329) Intern Med. 2021;60(3):463-468. (PMID: 33518613) Am J Hematol. 2016 Jun;91(6):575-80. (PMID: 26955792) |
| فهرسة مساهمة: | Keywords: BCMA; CNS involvement; Elranatamab; bispecific Ab; multiple myeloma |
| المشرفين على المادة: | 0 (Antibodies, Bispecific) 0 (B-Cell Maturation Antigen) |
| تواريخ الأحداث: | Date Created: 20231030 Date Completed: 20231031 Latest Revision: 20231105 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC10611496 |
| DOI: | 10.3389/fimmu.2023.1276295 |
| PMID: | 37901215 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2023.1276295 |